It has been demonstrated that TF-EVs promote thrombosis in PDAC patients, while baseline TF levels at the start point of chemotherapy constitute a predictive factor of cancer-related thromboembolism, as was demonstrated in Japanese PDAC patient cohorts [154]. The gene discussed is TF; the disease is cancer.